PF-06821497
- Generic Name
- PF-06821497
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24Cl2N2O5
- CAS Number
- 1844849-10-0
- Unique Ingredient Identifier
- S4L4MM20B6
- Background
PF-06821497 is under investigation in clinical trial NCT03460977 (PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 900
- Registration Number
- NCT06629779
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇺🇸AUC Urologists, LLC, Myrtle Beach, South Carolina, United States
🇺🇸Carolina Urologic Research Center, LLC, Myrtle Beach, South Carolina, United States
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT06551324
- Locations
- 🇨🇳
Tongji Hospital of Tongji University, Shanghai, Shanghai, China
🇯🇵Keio university hospital, Shinjuku-ku, Tokyo, Japan
🇰🇷Samsung Medical Center, Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath